Search bioRxiv⌕ Search

Biology subjects

Emran, T. B.

Publications and source records attributed to Emran, T. B..

2 recordsLinked to original sources

Structural characterization of a novel luciferase-like-monooxygenase from Pseudomonas meliae an in silico approach

BackgroundLuciferase is a well-known oxidative enzyme that produces bioluminescence. The Pseudomonas meliae is a plant pathogen that causes wood rot on nectarine and peach and possesses a luciferase-like monooxygenase. After activation, it produces bioluminescence, and the pathogens bioluminescence is a visual indicator of diseased plants. MethodsThe present study aims to model and characterize the luciferase-like monooxygenase protein in P. meliae for its similarity to well-established luciferase. In this study, the luciferase-like monooxygenase from P. meliae infects chinaberry plants has been modeled first and then studied by comparing it with existing known luciferase. Also, the similarities between uncharacterized luciferase from P. meliae and template from Geobacillus thermodenitrificans were analyzed to find the novelty of P. meliae. ResultsThe results suggest that the absence of bioluminescence in P. meliae could be due to the evolutionary mutation in positions 138 and 311. The active site remains identical except for two amino acids; P. meliae Tyr138 instead of His138 and Leu311 instead of His311. Therefore, the P. meliae will have a potential future application, and mutation of the residues 138 and 311 can be restored luciferase light-emitting ability. ConclusionsThis study will help further improve, activate, and repurpose the luciferase from P. meliae as a reporter for gene expression.

bioinformatics↗

Baculovirus-inducing fast-acting innate immunity kills Plasmodium liver stages

Baculovirus (BV), an enveloped insect virus with a circular double-stranded DNA genome, possesses unique characteristics that induce strong innate immune responses in mammalian cells. Here, we show that BV administration not only sterilely protects BALB/c mice for at least 7 days from subsequent Plasmodium berghei sporozoite infection but also eliminates existing liver-stage parasites completely, effects superior to those of primaquine, and does so in a TLR9-independent manner. Six hours post-BV administration, IFN- and IFN-{gamma} were robustly produced in serum, and RNA transcripts of interferon-stimulated genes were drastically upregulated in the liver. The in vivo passive transfer of post-BV administration serum effectively eliminated liver-stage parasites, and IFN- neutralization abolished this effect, indicating that the BV liver-stage parasite killing mechanism is downstream of the type I IFN signaling pathway. Our results demonstrate that BV is a potent IFN-inducing prophylactic and therapeutic agent with great potential for further development as a new malaria vaccine and/or anti-hypnozoite drug.

immunology↗